This site uses cookies to improve your experience. To help us insure we adhere to various privacy regulations, please select your country/region of residence. If you do not select a country, we will assume you are from the United States. Select your Cookie Settings or view our Privacy Policy and Terms of Use.
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Used for the proper function of the website
Used for monitoring website traffic and interactions
Cookie Settings
Cookies and similar technologies are used on this website for proper function of the website, for tracking performance analytics and for marketing purposes. We and some of our third-party providers may use cookie data for various purposes. Please review the cookie settings below and choose your preference.
Strictly Necessary: Used for the proper function of the website
Performance/Analytics: Used for monitoring website traffic and interactions
Jennifer Mathieu, director of government relations at the Academy of Managed Care Pharmacy (AMCP), tells us why the organisation backed the pre-approval information exchange (PIE) Act of 2022 and how the legislation will empower companies to share information with healthcare payers and plans during the FDA approval process. .
That said, while industry is already scrutinised from within, increased public pressure for transparency will require all clinical trial experts (including regulators) to communicate proactively with the public. Fortunately, many of the issues in this space are due to very fixable communication deficiencies.
Digital technology is transforming the way that healthcare is practiced and delivered, with areas like digital therapeutics forging ahead to complement traditional medical approaches and augment patientcare. We’ll be looking at how digital and traditional approaches to medicine are being combined to improve patient outcomes.
“So many more drugs are coming to market, and if you look at what the FDA has done over the last five years with approvals versus the actual pool of individuals to speak with, there’s a vast change in the need and the demand,” Lapolla states. Influential individuals. “It’s about digging deeper. .
Medical affairs in Pharma are often seen as a central agency that works within a healthcare company and prioritize communication among life science organizations, medical professionals, healthcare providers, and patients. Medical affairs definition uses clinical and scientific information to communicate the efficiency of a drug.
For this reason alone, it’s important to see them as partners and collaborators in the process of drug development, rather than them being the ‘necessary evil’ that maybe characterised some previous approaches to patientcare during trials. About Prime Global.
Leading companies are now investing heavily in patient engagement training, signaling a big shift in industry priorities. This change is further driven by major regulatory bodies emphasizing Patient-Focused Drug Development (PFDD). This education can be delivered through various formats, such as webinars, videos, and written materials.
Food and Drug Administration (FDA) has to undergo several rigorous phases before approving new medications. Once the FDA approves a new drug, it means that when using this drug for an approved condition, the potential benefits outweigh the potential risks. Given to a patient population for which they do not have FDA approval.
Small Dispensers and the 6/12/2024 FDA Announcement Concerning DSCSA This week’s article on the recent DSCSA postponement comes from PRS Pharmacy Services. If the FDA or another regulator requests DSCSA transaction data, the DSCSA regulations give you up to 48 hours to respond. The original article can be found HERE.
Clinical trials are the engine for pharmaceutical innovation, but their means of capturing and communicating data are stuck in the past. In most cases, the EHRs and EDCs don’t communicate, so in order to share that data with trial organisers, staff members at medical centres must manually copy data between the EHR and an EDC.
According to the FDA, there are over 20,000 medications approved. In the physician’s office, when you put electronic health records (EHRs) with algorithms and artificial intelligence into the hands of your team pharmacist, you have an overwhelming opportunity to improve clinical benefits and even greater opportunity to improve patientcare.
A recent analysis suggests changes to primary endpoints occur frequently in randomised clinical trials in oncology, representing a risk of suboptimal – or even potentially harmful – patientcare, together with outcome reporting bias. Nevertheless, it is incumbent on trialists to communicate such changes.
PQA offers a competitive Advanced Pharmacy Practice Experiential (APPE) Rotation for pharmacy students, which provides experiential learning opportunities in non-profit association management, medication use quality education, communications, research and performance measurement. Applications for the 2024-25 year are now being accepted.
Plecanatide : This is one of the newest medications for IBS-C that has been approved by the FDA. Plecanatide is recommended by the ACG for overall symptomatic improvement in IBS-C patients. Lubiprostone : This medication is often recommended for symptomatic improvement in IBS-C patients. 2000;46(4):493-499. doi:10.1136/gut.46.4.493;
The FDA has said it will wait for additional results from last week’s trial showing an increased risk of cardiac side effects with Pfizer’s arthritis blockbuster Xeljanz before deciding on further action. We will communicate our final conclusions and recommendations when we have completed our review or have more information to share.”.
Before starting opioid therapy for subacute or chronic pain, clinicians should discuss with patients the realistic benefits and known risks of opioid therapy, should work with patients to establish treatment goals for pain and function, and should consider how opioid therapy will be discontinued if benefits do not outweigh risks.
Because the way your company communicates its value to patients, healthcare providers, and stakeholders can mean the difference between success and failure. Videos, testimonials, and community initiatives show real-life impacts, creating a powerful connection with the audience. Why does this matter?
Digital health is transforming the health care landscape through new technologies and platforms in patientcare management, conducting of clinical trials, patient data collection, and the diagnosis and treatment of disease. Challenges & Opportunities in Emerging Digital Health Technologies. Ryan Hoshi. James Wabby.
Digital health is transforming the health care landscape through new technologies and platforms in patientcare management, conducting of clinical trials, patient data collection, and the diagnosis and treatment of disease. Challenges & Opportunities in Emerging Digital Health Technologies. Ryan Hoshi. James Wabby.
By analysing prescription data across multiple sources, augmented analytics can look at the medical conditions, patient demographics, and specialty areas for which drugs are most widely prescribed. One example of this use case is a pharmaceutical company that recently gained FDA approval for a rare cancer treatment.
These variabilities include limiting pharmacists’ authority to order and administer vaccines, restricting types of vaccines authorized, limiting vaccine administration by pharmacy technicians and student pharmacists, and restricting access based on patient demographics such as age.
Standard puberty blockers include Gonadotrophin Releasing Hormone (GnRH) analogues like Trelstar (triptorelin), Supprelin (Histrelin), and Zoladex (Goserelin), are only prescribed off label in the US and UK for gender affirming care. Please check your email to download the Report.
The Digital Transformation of Patient Marketing Technology has revolutionized how pharma communicates with patients. Brands like Ozempic have mastered this by offering user-friendly tools and support hubs tailored to the patient journey. FAQs What is patient marketing in pharma?
We organize all of the trending information in your field so you don't have to. Join 5,000+ users and stay up to date on the latest articles your peers are reading.
You know about us, now we want to get to know you!
Let's personalize your content
Let's get even more personalized
We recognize your account from another site in our network, please click 'Send Email' below to continue with verifying your account and setting a password.
Let's personalize your content